Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ECYT's Cash to Debt is ranked higher than
81% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. ECYT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ECYT' s Cash to Debt Range Over the Past 10 Years
Min: 0.69  Med: 5004.99 Max: No Debt
Current: No Debt
Equity to Asset 0.96
ECYT's Equity to Asset is ranked higher than
96% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ECYT: 0.96 )
Ranked among companies with meaningful Equity to Asset only.
ECYT' s Equity to Asset Range Over the Past 10 Years
Min: -3.01  Med: 0.54 Max: 0.96
Current: 0.96
-3.01
0.96
Interest Coverage No Debt
ECYT's Interest Coverage is ranked higher than
73% of the 393 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ECYT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ECYT' s Interest Coverage Range Over the Past 10 Years
Min: 5027  Med: 10000.00 Max: 9999.99
Current: No Debt
5027
9999.99
F-Score: 3
Z-Score: 13.38
M-Score: -105.03
WACC vs ROIC
16.09%
-155.22%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -58297.22
ECYT's Operating margin (%) is ranked lower than
98% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -66.05 vs. ECYT: -58297.22 )
Ranked among companies with meaningful Operating margin (%) only.
ECYT' s Operating margin (%) Range Over the Past 10 Years
Min: -59961.43  Med: -524.60 Max: 7.15
Current: -58297.22
-59961.43
7.15
Net-margin (%) -57319.44
ECYT's Net-margin (%) is ranked lower than
98% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -68.08 vs. ECYT: -57319.44 )
Ranked among companies with meaningful Net-margin (%) only.
ECYT' s Net-margin (%) Range Over the Past 10 Years
Min: -58957.14  Med: -566.87 Max: 7.76
Current: -57319.44
-58957.14
7.76
ROE (%) -21.96
ECYT's ROE (%) is ranked higher than
57% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -31.46 vs. ECYT: -21.96 )
Ranked among companies with meaningful ROE (%) only.
ECYT' s ROE (%) Range Over the Past 10 Years
Min: -492.46  Med: -19.20 Max: 3.72
Current: -21.96
-492.46
3.72
ROA (%) -21.20
ECYT's ROA (%) is ranked higher than
54% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -26.29 vs. ECYT: -21.20 )
Ranked among companies with meaningful ROA (%) only.
ECYT' s ROA (%) Range Over the Past 10 Years
Min: -86.45  Med: -21.10 Max: 2.91
Current: -21.2
-86.45
2.91
ROC (Joel Greenblatt) (%) -1140.78
ECYT's ROC (Joel Greenblatt) (%) is ranked lower than
63% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. ECYT: -1140.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ECYT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3920.55  Med: -1139.18 Max: 139.85
Current: -1140.78
-3920.55
139.85
Revenue Growth (3Y)(%) -87.30
ECYT's Revenue Growth (3Y)(%) is ranked lower than
94% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ECYT: -87.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ECYT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -87.30 Max: 522.1
Current: -87.3
0
522.1
EBITDA Growth (3Y)(%) 29.10
ECYT's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 497 Companies
in the Global Biotechnology industry.

( Industry Median: -0.30 vs. ECYT: 29.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ECYT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -70.60 Max: 29.1
Current: 29.1
0
29.1
EPS Growth (3Y)(%) 26.90
ECYT's EPS Growth (3Y)(%) is ranked higher than
80% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ECYT: 26.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ECYT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -71.00 Max: 26.9
Current: 26.9
0
26.9
» ECYT's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-07)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ECYT Guru Trades in Q1 2015

Jim Simons 379,100 sh (-29.46%)
» More
Q2 2015

ECYT Guru Trades in Q2 2015

Jim Simons 386,112 sh (+1.85%)
» More
Q3 2015

ECYT Guru Trades in Q3 2015

Jim Simons 72,699 sh (-81.17%)
» More
Q4 2015

ECYT Guru Trades in Q4 2015

Jim Simons 51,161 sh (-29.63%)
» More
» Details

Insider Trades

Latest Guru Trades with ECYT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.97
ECYT's P/B is ranked higher than
92% of the 843 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. ECYT: 0.97 )
Ranked among companies with meaningful P/B only.
ECYT' s P/B Range Over the Past 10 Years
Min: 0.71  Med: 1.71 Max: 11.65
Current: 0.97
0.71
11.65
Current Ratio 28.26
ECYT's Current Ratio is ranked higher than
95% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. ECYT: 28.26 )
Ranked among companies with meaningful Current Ratio only.
ECYT' s Current Ratio Range Over the Past 10 Years
Min: 1.81  Med: 2.86 Max: 28.26
Current: 28.26
1.81
28.26
Quick Ratio 28.26
ECYT's Quick Ratio is ranked higher than
95% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ECYT: 28.26 )
Ranked among companies with meaningful Quick Ratio only.
ECYT' s Quick Ratio Range Over the Past 10 Years
Min: 1.81  Med: 2.86 Max: 28.26
Current: 28.26
1.81
28.26
Days Sales Outstanding 45.63
ECYT's Days Sales Outstanding is ranked higher than
68% of the 603 Companies
in the Global Biotechnology industry.

( Industry Median: 66.24 vs. ECYT: 45.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
ECYT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.66  Med: 41.34 Max: 59.87
Current: 45.63
3.66
59.87

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.02
ECYT's Price/Net Cash is ranked higher than
95% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 5.74 vs. ECYT: 1.02 )
Ranked among companies with meaningful Price/Net Cash only.
ECYT' s Price/Net Cash Range Over the Past 10 Years
Min: 1.01  Med: 2.24 Max: 7.91
Current: 1.02
1.01
7.91
Price/Net Current Asset Value 1.01
ECYT's Price/Net Current Asset Value is ranked higher than
95% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 5.40 vs. ECYT: 1.01 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ECYT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1  Med: 2.21 Max: 6.59
Current: 1.01
1
6.59
Price/Tangible Book 0.99
ECYT's Price/Tangible Book is ranked higher than
93% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. ECYT: 0.99 )
Ranked among companies with meaningful Price/Tangible Book only.
ECYT' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.98  Med: 1.28 Max: 4.38
Current: 0.99
0.98
4.38
Price/Median PS Value 407.00
ECYT's Price/Median PS Value is ranked lower than
100% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ECYT: 407.00 )
Ranked among companies with meaningful Price/Median PS Value only.
ECYT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.36  Med: 0.91 Max: 401
Current: 407
0.36
401
Earnings Yield (Greenblatt) (%) 2004.43
ECYT's Earnings Yield (Greenblatt) (%) is ranked lower than
99.99% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. ECYT: 2004.43 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ECYT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.4  Med: 8.40 Max: 5200
Current: 2004.43
3.4
5200

More Statistics

Revenue(Mil) $0
EPS $ -0.98
Beta1.89
Short Percentage of Float10.35%
52-Week Range $2.65 - 6.35
Shares Outstanding(Mil)42.15

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil)
EPS($) -1.05 -1.00 -0.87
EPS without NRI($) -1.05 -1.00 -0.87

Business Description

Industry: Biotechnology » Biotechnology
Compare:ROCO:4911, XKRX:041910, NAS:CBMG, NAS:FLKS, XKRX:011000, NAS:CYTR » details
Traded in other countries:9EY.Germany,
Endocyte Inc was incorporated in the State of Indiana in 1995 and was reincorporated in the State of Delaware in 2001. The Company completed its initial public offering on April 2, 2014. The Company is a biopharmaceutical company. The Company is engaged in developing targeted therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging agents. The Company is also developing companion imaging agents for each of its SMDCs that are designed to identify the patients whose disease over-expresses the target of the therapy and who are therefore likely to benefit from treatment. Its SMDC candidate, vintafolide, targets the folate receptor, which is frequently over-expressed on cancer cells. The Company's SMDC Pipeline products include Vintafolide designed to deliver a cytotoxic drug payload directly to folate receptors that are over-expressed on cancer cells, with low toxicity to healthy cells; EC1456 is a second generation folate receptor-targeted SMDC. It is a conjugate of folate and an anti-cancer drug payload of tubulysin, a microtubule destabilizer; EC1169 is non-folate targeted SMDC and is designed to specifically target PSMA; EC1788 is a folate receptor-targeted SMDC in preclinical development with a very potent DNA alkylator drug; EC1669 is a folate receptor-targeted SMDC in preclinical development for treatment in inflammatory diseases; and EC0371 is a folate receptor-targeted SMDC in preclinical development for treatment of polycystic kidney disease. The Company faces competition from other pharmaceutical companies, biotechnology companies, public and private universities and research organizations. Government authorities in the United States (including federal, state and local authorities) and in other countries regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging, distribution, post-approval monitoring and reporting, advertising and promotion, and export and import of pharmaceutical products.
» More Articles for ECYT

Headlines

Articles On GuruFocus.com
Merck: Ready to Rise on New Drugs Apr 18 2012 

More From Other Websites
Endocyte Announces First Quarter 2016 Earnings Conference Call Apr 27 2016
Endocyte Announces First Quarter 2016 Earnings Conference Call Apr 27 2016
Edited Transcript of ECYT earnings conference call or presentation 2-Mar-16 9:30pm GMT Apr 25 2016
ENDOCYTE INC Files SEC form 8-K, Regulation FD Disclosure Apr 20 2016
ENDOCYTE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Apr 19 2016
Endocyte Announces Promising Preclinical Data for Application of SMDC Technology in CAR T Cell... Apr 19 2016
Endocyte Announces Promising Preclinical Data for Application of SMDC Technology in CAR T Cell... Apr 19 2016
ETF’s with exposure to Endocyte, Inc. : April 14, 2016 Apr 14 2016
Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting... Apr 11 2016
Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting... Apr 11 2016
Endocyte (ECYT): Strong Industry, Solid Earnings Estimate Revisions Mar 28 2016
ETF’s with exposure to Endocyte, Inc. : March 23, 2016 Mar 23 2016
ENDOCYTE INC Financials Mar 12 2016
Endocyte, Inc. :ECYT-US: Earnings Analysis: 2015 By the Numbers Mar 09 2016
ENDOCYTE INC Files SEC form 10-K, Annual Report Mar 08 2016
Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q4 Mar 03 2016
Endocyte reports 4Q loss Mar 02 2016
Endocyte reports 4Q loss Mar 02 2016
Endocyte Inc Earnings Call scheduled for 4:30 pm ET today Mar 02 2016
ENDOCYTE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK